Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
A first in human study of people with chronic hepatitis B, where all participants will receive the new drug PBGENE-HBV. This study will use increasing dose amounts of the drug to see how safe and bearable it is. The study will also test how well PBGENE-HBV works and how it is processed by the body.
Chongqing Precision Biotech Co., Ltd
Chronic Hepatitis B
1 trial -
A first-in-human study to learn about how safe BAY 3375968 is, how it moves into, through, and out of the body, and to find its best dose when given alone or with pembrolizumab in participants with advanced solid tumors
Bayer AG
Advanced solid tumors
1 trial -
A first-in-human study to learn how safe the study treatment BAY2862789 is, to find the best dose, how it affects the body, what maximum amount can be given, how it moves into, through and out of the body, and how it acts on different tumors in participants with advanced solid tumors
Bayer AG
Advanced solid tumors, Non-small cell lung cancer
1 trial -
A first-in-human trial to evaluate safety, tolerability, and pharmacokinetics of single and multiple oral doses of Debio 1453P in healthy adults
Alphapharm Pty Ltd
Sexual Transmitted Infection (STI)
1 trial -
A first-in-human, randomized, double-blind, placebo-controlled, three-part study assessing the safety, tolerability, pharmacokinetics and pharmacodynamics of BP1.15205 after single and repeated oral ascending doses, including the BP1.15205 effect on cardiac repolarization, as well as an exploratory assessment of the food effect on the pharmacokinetics of BP1.15205 in healthy participants
Bioprojet Pharma
Narcolepsy
1 trial -
A first-in-human, randomized, participant and investigator blinded, placebo-controlled single and multiple ascending dose study to assess the safety, tolerability and pharmacokinetics of HJB647 in healthy participants and otherwise healthy participants with elevated blood pressure, with an open-label CYP3A inhibitor drug-drug interaction part
Novartis Pharmaceuticals
Heart failure (HF)
1 trial -
A multicentric, open-label, non-randomized study to evaluate the pharmacokinetic, safety and tolerability of ITF2357 given as an oral single 50 mg dose in participants with chronic hepatic impairment relative to matched participants with normal hepatic function.
Italfarmaco S.p.A.
Participants with normal hepatic function, Participants with moderate HI, Participants with mild HI
1 trial -
A phase 1 multi-centre, randomized, single-blind, steady-state study to evaluate pharmacokinetics, pharmacodynamics, safety and tolerability after multiple-dose administration of three different doses of naronapride in patients with moderate idiopathic or diabetic gastroparesis compared to healthy subjects
Dr. Falk Pharma GmbH
Idiopathic or diabetic gastroparesis
1 trial -
A phase 1 study to assess the mass balance, pharmacokinetics, metabolism, and excretion of GSBR-1290, containing a microtracer dose of [14C] GSBR-1290, in healthy participants
Structure Therapeutics
Not applicable - Healthy volonteers
1 trial -
A phase 1, randomised, double-blind, placebo-controlled, single ascending dose and multiple ascending dose study to evaluate the safety, tolerability, and pharmacokinetics in healthy adult subjects after subcutaneous injection of TISA-818-Inj-5mg/mL.
Lacuna Pharma Pty Ltd
Idiopathic pulmonary fibrosis
1 trial -
A phase I dose finding study of oral TNO155 in adult patients with advanced solid tumors
Novartis Pharmaceuticals
Advanced solid tumors
1 trial -
A phase Ib, open-label, ascending dose study to assess safety, tolerability and pharmacokinetics of PIT565 in participants with rheumatoid arthritis (RA)
Novartis Pharmaceuticals
Rheumatoid Arthritis
1 trial -
A phase Ib, open-label, ascending dose study with step-up doses to assess safety, tolerability, and pharmacokinetics of PIT565 in participants with systemic lupus erythematosus (SLE)
Novartis Pharmaceuticals
Systemic Lupus Erythematosus
1 trial -
A pilot, open label, single dose, randomized, four-period, four-sequence, four-treatment crossover, comparative bioavailability study of UDCA PMCS 500 mg formulation 1 film-coated tablets (test 1 formulation), and UDCA PMCS 500 mg formulation 2 film-coated tablets (test 2 formulation), and UDCA PMCS 500 mg formulation 3 film-coated tablets (test 3 formulation), and reference formulation in healthy, male and female volunteers under fasting conditions.
s.r.o.
UDCA causes a reduction in cholesterol saturation of the bile by inhibiting cholesterol absorption in the intestine and reducing cholesterol secretion into the bile. Presumably, cholesterol gallstones are gradually dissolved by dispersion of the cholesterol and formation of liquid crystals.
1 trial -
A randomised, double-blind, placebo-controlled phase Ib trial evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple doses of ACD856 in healthy participants
Lacuna Pharma Pty Ltd
Depression, Cognitive dysfunction, Alzheimer’s disease
1 trial -
A randomised, open-label, parallel group study to compare the pharmacokinetics and pharmacodynamics of NEODIDRO® 0.266 mg vs DIBASE® 25,000 IU oral doses in male and female patients.
Verona Pharma Ireland Limited
Patients with low Vitamin D plasma level
1 trial -
A randomized double-blind placebo-controlled phase 1 study on the safety, tolerability and pharmacokinetics/-dynamics of escalating single intravenous doses of AK1967 (Procizumab) in healthy male volunteers
Lacuna Pharma Pty Ltd
Circulatory shock
1 trial -
A randomized, Phase 1b, single-center, observer-blind, active-controlled study to evaluate the safety, immunogenicity, and immunological mechanisms of one single administration of TETRALITE influenza vaccine at two dose levels of LiteVax Adjuvant, in healthy participants aged 60 years and older and in healthy participants aged 18 to 50 years.
Teva Pharma GmbH
Influenza
1 trial -
A randomized, Phase I, single-center, observer-blind, active-controlled study to evaluate the safety, tolerability and immunogenicity of one single administration of PCV-LITE, a novel adjuvanted pneumococcal conjugate vaccine at one dose level of LiteVax Adjuvant, in healthy participants aged 18-50 years.
Teva Pharma GmbH
Pneumococcal infection
1 trial -
A randomized, double-blind, placebo-controlled, single and multiple-dose-escalation, phase 1 study in healthy volunteers and patients with ulcerative colitis to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of GRT-001 (MONOlith trial)
Rani Therapeutics Holdings
Ulcerative colitis
1 trial -
A randomized, open-label, single dose, 2-way crossover bioequivalence study comparing apixaban 5 mg hard capsules (PG412 [Celon Pharma]) vs apixaban 5 mg film-coated tablets (Eliquis [Bristol-Myers Squibb]) under fasting conditions in healthy volunteers
Lacuna Pharma Pty Ltd
Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II). Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.
1 trial -
A randomized, open-label, single dose, cross-over study to evaluate the drug-drug interaction between Proscar 5 mg, film-coated tablets and Cialis 5 mg film-coated tablets when co-administered versus the administration of each product alone in healthy volunteers under fasting conditions. Study no. FIN-TAD-DDI-03-24
Lacuna Pharma Pty Ltd
healthy male subjects
1 trial -
A randomized, single dose, cross-over bioavailability study comparing the drug-drug interaction between telmisartan tablets, indapamide tablets, and amlodipine tablets when co-administered versus the administration of each product alone in three arms to healthy volunteers under fasting conditions.
s.r.o.
high blood pressure
1 trial -
A randomized, single dose, cross-over, replicated, open-label bioequivalence study comparing indacaterol/glycopyrronium (85/43mcg inhalation powder hard capsules) (PG341 [Celon Pharma] vs Ultibro Breezhaler [Novartis])
Lacuna Pharma Pty Ltd
Maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD)
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources